Perosphere, Daiichi Sankyo to test antidote to edoxaban

04/26/2013 | Pharmaceutical Business Review Online

Perosphere and Daiichi Sankyo have agreed to work together on a clinical trial that will assess the efficacy and safety of PER977, a drug being designed to reverse the anticoagulant effect of edoxaban, a factor Xa inhibitor. In preclinical testing, PER977 attached to heparins and factor Xa and IIa inhibitors but not to blood proteins.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID